Evidence map›Paper›PMID 28168589›Full record

ArticleEJNMMI research2017

Impact of PET acquisition durations on image quality and lesion detectability in whole-body

Benjamin Noto, Florian Büther, Katharina Auf der Springe, Nemanja Avramovic, Walter Heindel, Michael Schäfers, Thomas Allkemper, Lars Stegger

Abstract read
In one paragraph

Article in EJNMMI research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. PET/MRI in prostate cancer: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2021
    Pooled it
  2. Article
  3. Article
  4. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Preclinical PET, PET/CT, and PET/MRI.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  6. Optimizing Attenuation Correction inDiagnostics (Basel, Switzerland) · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. The image quality, lesion detectability, and acquisition time ofEuropean journal of nuclear medicine and molecular imaging · 2020
    Article
  11. Article
  12. EJNMMI physics · 2020
    Article
  13. Article
  14. Current status of theranostics in prostate cancer.European journal of nuclear medicine and molecular imaging · 2018
    Review
  15. Clinical performance ofEuropean journal of nuclear medicine and molecular imaging · 2018
    Article
  16. The accuracy ofEuropean journal of nuclear medicine and molecular imaging · 2017
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Benjamin NotoDepartment of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Florian BütherDepartment of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. butherf@uni-muenster.de.
Katharina Auf der SpringeInstitute for Clinical Radiology, University Hospital Münster, Münster, Germany.
Nemanja AvramovicDepartment of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Walter HeindelInstitute for Clinical Radiology, University Hospital Münster, Münster, Germany.
Michael SchäfersDepartment of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Thomas AllkemperInstitute for Clinical Radiology, University Hospital Münster, Münster, Germany.
Lars SteggerDepartment of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile

resultsDecreased PET acquisition durations resulted in a significantly increased incidence of halo artefacts around kidneys and bladder, decreased lesion detectability and lower SUV as well as markedly lower arm attenuation values: Halo artefacts were present in 5 out of 12 cases at 300-s duration, in 6 at 180 s, in 10 at 90 s, and in 11 cases at 30 s. Using attenuation data of the 300 s scans restored artefact occurrence to the original 300-s level. Prompt gamma correction only led to small improvements in terms of artefact occurrence and size. Of the 141 detected lesions in the 300-s images one lesion was not detected at 180 s, 28 at 90 s, and 64 at 30 s. Using the 300-s attenuation map decreased non-detectability of lesions to zero at 180 s, 9 at 90 s, and 52 at 30 s. Attenuation maps at 90 and 30 s demonstrated markedly lower mean arm attenuation values (0.002 cm

conclusionsShort acquisition durations of less than 3 minutes per bed position result in unacceptable image artefacts and decreased diagnostic performance in current whole-body

Indexed as

Attenuation correctionHalo artefactsPET-MRIProstate cancerPSMAScatter correction

Identifiers

PMID28168589
PMCPMC5293699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.